Back to Search
Start Over
Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures
- Source :
- BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019), BMC Cancer
- Publication Year :
- 2019
-
Abstract
- Background Receptor tyrosine kinase (RTK) inhibitors are frequently used to treat cancers and the results have been mixed, some of these small molecule drugs are highly successful while others show a more modest response. A high number of studies have been conducted to investigate the signaling mechanisms and corresponding therapeutic influence of RTK inhibitors in order to explore the therapeutic potential of RTK inhibitors. However, most of these studies neglected the potential metabolic impact of RTK inhibitors, which could be highly associated with drug efficacy and adverse effects during treatment. Methods In order to fill these knowledge gaps and improve the therapeutic utilization of RTK inhibitors a large-scale computational simulation/analysis over multiple types of cancers with the treatment responses of RTK inhibitors was performed. The pharmacological data of all eight RTK inhibitor and gene expression profiles of 479 cell lines from The Cancer Cell Line Encyclopedia were used. Results The potential metabolic impact of RTK inhibitors on different types of cancers were analyzed resulting in cancer-specific (breast, liver, pancreas, central nervous system) metabolic signatures. Many of these are in line with results from different independent studies, thereby providing indirect verification of the obtained results. Conclusions Our study demonstrates the potential of using a computational approach on signature-based-analysis over multiple cancer types. The results reveal the strength of multiple-cancer analysis over conventional signature-based analysis on a single cancer type. Electronic supplementary material The online version of this article (10.1186/s12885-019-5804-0) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
Models, Molecular
Cancer Research
Systems biology
Antineoplastic Agents
lcsh:RC254-282
Receptor tyrosine kinase
Efficacy
03 medical and health sciences
0302 clinical medicine
Surgical oncology
Cell Line, Tumor
Neoplasms
Drug Discovery
Genetics
Medicine
Humans
Computer Simulation
ddc:610
Adverse effect
Protein Kinase Inhibitors
biology
business.industry
fungi
Computational Biology
Receptor Protein-Tyrosine Kinases
Computational modeling
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Small molecule
Cancer metabolism
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Receptor tyrosine kinase inhibitor
Cancer research
biology.protein
ddc:004
business
Transcriptome
Research Article
Treatment prediction
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019), BMC Cancer
- Accession number :
- edsair.doi.dedup.....27532d32e1e0b202680b3ce80b452cf1